Vor Bio will present Phase 3 clinical data for telitacicept in Sjögren’s disease at ACR Convergence 2025.
Quiver AI Summary
Vor Bio, a clinical-stage biotechnology company, announced that it will present clinical data from a Phase 3 study of telitacicept for treating primary Sjögren’s disease at the upcoming ACR Convergence 2025, taking place from October 24-29 in Chicago. This study, conducted in China and sponsored by RemeGen Co., Ltd, will be showcased as a late-breaking poster on October 28. Telitacicept, a novel dual-target fusion protein, selectively inhibits key cytokines involved in B cell survival, aiming to reduce the effects of autoimmune diseases. Currently, telitacicept is approved in China for several autoimmune conditions, and the data presentation follows a recent acceptance of a Biologics License Application by the National Medical Products Administration in China. Sjögren's disease, characterized by overactive B cells causing inflammation and various systemic complications, lacks disease-modifying therapies, highlighting the significance of telitacicept's potential impact in patient care.
Potential Positives
- Vor Bio is presenting clinical data from its Phase 3 study of telitacicept, highlighting the company's ongoing commitment to advancing treatments for autoimmune diseases.
- The presentation at ACR Convergence 2025 as a late-breaking poster signifies the importance of the study findings, potentially increasing visibility and recognition within the medical community.
- Telitacicept's approval for additional indications in China, including Sjögren’s disease, strengthens the company's product portfolio and market presence in the biotechnology industry.
Potential Negatives
- The press release highlights that telitacicept is still in clinical development stages and has not yet received approval for use outside of China, indicating potential limitations in market access and commercialization.
- The reliance on a collaborator, RemeGen, for clinical study sponsorship may raise concerns about Vor Bio's independence and control over the development and marketing of telitacicept.
- The description of Sjögren’s disease as "underdiagnosed" and the lack of existing effective disease-modifying therapies suggests a challenging market landscape and may indicate a higher risk for the success of telitacicept in addressing these medical needs.
FAQ
What is the recent announcement from Vor Bio?
Vor Bio announced clinical data for telitacicept in primary Sjögren’s disease will be presented at ACR Convergence 2025.
When will the presentation on telitacicept take place?
The late-breaking poster presentation will occur on October 28th, 2025, from 10:30 AM to 12:30 PM CT.
What is telitacicept used to treat?
Telitacicept is being developed to treat autoimmune diseases, specifically targeting conditions like primary Sjögren’s disease.
What is Sjögren’s disease?
Sjögren’s disease is a chronic autoimmune condition characterized by dry eyes and mouth, primarily affecting women.
Is telitacicept approved for any conditions?
Yes, telitacicept is approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VOR Insider Trading Activity
$VOR insiders have traded $VOR stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $VOR stock by insiders over the last 6 months:
- INTERCHANGE LLC REPROGRAMMED has made 0 purchases and 14 sales selling 6,192,892 shares for an estimated $11,878,375.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VOR Hedge Fund Activity
We have seen 16 institutional investors add shares of $VOR stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,329,810 shares (-67.4%) from their portfolio in Q2 2025, for an estimated $7,014,292
- UBS GROUP AG added 1,523,181 shares (+18015.2%) to their portfolio in Q2 2025, for an estimated $2,467,553
- LYNX1 CAPITAL MANAGEMENT LP removed 637,218 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $457,203
- HRT FINANCIAL LP added 474,575 shares (+inf%) to their portfolio in Q2 2025, for an estimated $768,811
- SCIENTECH RESEARCH LLC added 403,859 shares (+inf%) to their portfolio in Q2 2025, for an estimated $654,251
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 384,293 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $622,554
- JANE STREET GROUP, LLC added 330,857 shares (+169.9%) to their portfolio in Q2 2025, for an estimated $535,988
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VOR Analyst Ratings
Wall Street analysts have issued reports on $VOR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/14/2025
To track analyst ratings and price targets for $VOR, check out Quiver Quantitative's $VOR forecast page.
$VOR Price Targets
Multiple analysts have issued price targets for $VOR recently. We have seen 4 analysts offer price targets for $VOR in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.0 on 08/14/2025
- Jack Allen from Baird set a target price of $1.0 on 06/27/2025
- David Nierengarten from Wedbush set a target price of $0.4 on 06/26/2025
- Silvan Tuerkcan from JMP Securities set a target price of $6.0 on 05/09/2025
Full Release
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois.
Late-Breaking Presentation Details
Abstract Title: Efficacy and Safety of Telitacicept in Patients with Sjögren's Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Session: Late-Breaking Posters
Date & Time: Tuesday, October 28 th , 10:30 AM – 12:30 PM CT
In early September, RemeGen announced the acceptance by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China of its Biologics License Application (BLA) for primary Sjögren’s disease, which will become telitacicept’s fourth approved indication in China.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit
www.vorbio.com
.
About Telitacicept
Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a placebo adjusted 4.83-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) at 24 weeks, the primary endpoint of the trial.
Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, South America, and Asia-Pacific to support potential approval in the United States, Europe, and Japan.
About Sjögren’s Disease (formerly known as Sjögren’s Syndrome)
Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive inflammation, damaging moisture-producing glands and, in many cases, other organs. Hallmark symptoms include dry eyes and dry mouth, alongside fatigue, pain, and systemic complications affecting the skin, lungs, kidneys, and nervous system. About one-third of patients develop significant extraglandular involvement, and the disease carries an elevated lymphoma risk, often leading to substantial impairment in daily life.
One of the most common rheumatic autoimmune diseases, Sjögren’s remains underdiagnosed, with roughly half of cases unrecognized and women comprising the vast majority of patients. Despite its prevalence and burden, no systemic disease-modifying therapies exist; current care focuses on symptom management with incomplete relief.
Media & Investor Contacts:
Carl Mauch
[email protected]
Sarah Spencer
[email protected]
